Literature DB >> 18970933

Reduction of hepatocellular injury after common bile duct ligation using omega-3 fatty acids.

Sang Lee1, Sendia Kim, Hau D Le, Jonathan Meisel, Robbert A M Strijbosch, Vania Nose, Mark Puder.   

Abstract

PURPOSE: Bile duct obstruction and subsequent cholestasis produces hepatocellular injury and an inflammatory response. Fatty acid constitution of cell membranes plays a major role in the inflammatory cascade. Omega-3 fatty acids are antiinflammatory. We proposed that omega-3 fatty acid supplementation would reduce hepatocellular damage and cell death in a model of murine common bile duct ligation.
METHODS: Mice underwent bile duct ligation and were administered either control soy diet (omega-6) or Menhaden diet (omega-3), and parameters of liver injury were measured at postoperative days 1, 4, and 8. Serum was analyzed for liver function tests. Liver tissue was scored for histologic necrosis and inflammation, and apoptosis was qualitatively measured.
RESULTS: At day 8, comparing control and Menhaden, liver function tests were not significantly different. The H&E slides were analyzed and scored. At day 4, the mean necrosis scores for the Menhaden-fed group was 0.01 +/- 0.028 and 0.46 +/- 0.108 for the soy-fed group (P = .001) and at day 8, 0.420 +/- 0.107 and 1.22 +/- 0.132 (P < .001). The mean portal inflammation score for day 4 Menhaden-fed and soy-fed mice was 1.40 +/- 0.245 for both groups (P = 1.00) and for day 8, 1.80 +/- 0.200 and 2.80 +/- 0.200 (P = .008). At day 1, the median terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling scores of the Menhaden vs soy group were 6.0 and 0.0 (P < .001); day 4, 24.0 and 3.0 (P < .001); and day 8, 0.0 and 3.0 (P < .001), respectively.
CONCLUSION: Although there appears to be a trend toward biochemical protection and a marked reduction of necrosis and inflammation, there was no significant liver function test difference between control and Menhaden groups. Considering our data of blunted histologic hepatotoxicity with omega-3 fatty acid supplementation, we hypothesize that this may be a method of reducing long-term complications of liver injury secondary to diseases of cholestasis such as biliary atresia, namely fibrosis and cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18970933     DOI: 10.1016/j.jpedsurg.2008.05.030

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  9 in total

Review 1.  Treatment of parenteral nutrition-associated liver disease: the role of lipid emulsions.

Authors:  Prathima Nandivada; Sarah J Carlson; Melissa I Chang; Eileen Cowan; Kathleen M Gura; Mark Puder
Journal:  Adv Nutr       Date:  2013-11-06       Impact factor: 8.701

2.  Omega-3 long chain polyunsaturated Fatty acids for treatment of parenteral nutrition-associated liver disease: a review of the literature.

Authors:  Emma M Tillman; Richard A Helms
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

3.  [13C]Methionine breath test to assess intestinal failure-associated liver disease.

Authors:  Debora Duro; Shimae Fitzgibbons; Clarissa Valim; Chi-Fu Jeffrey Yang; David Zurakowski; Melanie Dolan; Lori Bechard; Yong Ming Yu; Christopher Duggan; Tom Jaksic
Journal:  Pediatr Res       Date:  2010-10       Impact factor: 3.756

4.  Oral administration of eicosapentaenoic acid suppresses liver fibrosis in postoperative patients with biliary atresia.

Authors:  Wataru Sumida; Hiroo Uchida; Takahisa Tainaka; Chiyoe Shirota; Akinari Hinoki; Takazumi Kato; Kazuki Yokota; Kazuo Oshima; Ryo Shirotuki; Kosuke Chiba; Yujiro Tanaka
Journal:  Pediatr Surg Int       Date:  2018-07-28       Impact factor: 1.827

5.  Different polyunsaturated fatty acid profiles in patients with biliary atresia after successful Kasai operation and liver transplantation.

Authors:  Wataru Sumida; Kenitiro Kaneko; Yasuyuki Ono; Takahisa Tainaka; Hisami Ando
Journal:  Pediatr Surg Int       Date:  2009-01-31       Impact factor: 1.827

Review 6.  Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step.

Authors:  Ralf Weiskirchen
Journal:  Front Pharmacol       Date:  2016-01-07       Impact factor: 5.810

7.  Omega-3 Polyunsaturated Fatty Acid for Cholestasis due to Bile Duct Paucity.

Authors:  Sun Hwan Bae; Hee Sun Park; Hye Seung Han; Ik Jin Yun
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2014-06-30

8.  N-3 Polyunsaturated Fatty Acids Stimulate Bile Acid Detoxification in Human Cell Models.

Authors:  Anna Cieślak; Jocelyn Trottier; Mélanie Verreault; Piotr Milkiewicz; Marie-Claude Vohl; Olivier Barbier
Journal:  Can J Gastroenterol Hepatol       Date:  2018-04-05

9.  Reversibility of hepatic histological damage after surgical temporary obstruction of the common bile duct in a murine model.

Authors:  H Juárez Olguín; J L Figueroa Hernández; D Calderón Guzman; R Alemón Medina
Journal:  Int J Biomed Sci       Date:  2011-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.